Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SCLC with known UGT1A genotype.~* Patients who have received at least 1 prior platinum-based chemotherapy.~* Life expectancy of 3 months or more.~* Measurable disease.~Exclusion Criteria:~* Patients with UGT1A polymorphism.~* Currently receiving chemotherapy.~* Pregnant and nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab and Irinotecan (Type: EXPERIMENTAL): Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)

Based on this trial design, predict the completion outcome and termination type (if applicable).